Recombinant activated factor VII in cardiac surgery - first, do no harm. J Cardiothorac Surg 2007; 2:50. A brief commentary explaining why things can, and in fact do, go wrong in some patients receiving rFVIIa after cardiac surgery and should be read by all those contemplating the use of ...
Bleeding, Blood transfusion, Cardiac Surgery, Recombinant Factor VIIaObjective: To describe our experience in the use of recombinant activated factor VII (Novoseven) in the management of post operative bleeding in cardiac surgery at Queen Alia Heart Institute / King Hussein Medical Center-Jordan.The ...
人凝血酶原复合物(Octapharma): 一种F10调节剂、factor IX调节剂、factor VII调节剂药物,由Octapharma AG (Octapharma AG)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: F10调节剂(凝血因子X调节剂),factor IX调节剂(凝血因子IX调节剂),factor VII调节剂(
Effect of Vitamin D supplementation on postoperative outcomes in cardiac surgery patients: a systematic review. J Card Crit Care TSS. 2022;6(03):195–200. Article Google Scholar Moola S, Munn Z, Tufanaru C. Systematic reviews of etiology and risk. Adelaide: JBI; 2020. https://doi.org/...
Chylous effusions frequently occur after cardiac surgery due to severe damage to the lymphatic system, thus indicating that the insertion of a chest tube may be necessary. Factor XIII (FXIII) is discussed as being essential for wound healing. The aim of this retrospective study was to evaluate...
Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be sus...
This parallel-group randomized pilot study assesses whether 4-factor prothrombin complex concentrate can substitute for frozen plasma in the treatment of bleeding related to coagulation factor deficiency in adult patients during and after cardiac surgery. ...
We excluded brainstem ICH, known secondary causes of ICH (eg, vascular malformation, tumor), planned surgery for ICH evacuation (but intraventricular drains were allowed), and planned withdrawal of care. To maximize safety of rFVIIa, we excluded patients with cardiac or cerebral ischemia or ...
Mattila A-L, Perheentupa J, Pesonen K, Viinikka L (1985) Epidermal growth factor in human urine from birth to puberty. J Clin Endocrinol Metab 61: 997–1000 Article PubMed CAS Google Scholar May JV, Buck PA, Schomberg DW (1987) Epidermal growth factor enhances [12 I]iodo-follicle-st...
The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in posi